Navigation Links
Moffitt researchers find cutaneous human papillomavirus infection a risk factor for skin cancer
Date:7/2/2012

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida, the German Cancer Research Center in Heidelberg, and the International Agency for Research on Cancer in Lyon, France, conducted a case control study and found associations between having antibodies to certain types of cutaneous human papillomavirus (HPV) and a kind of skin cancer called squamous cell carcinoma (SCC).

Their study, the first case-control study to investigate the association between SCC and cutaneous HPV types belonging to five different genera, appeared in a recent issue of Cancer Epidemiology, Biomarkers & Prevention, a journal published by the American Association for Cancer Research. The research was supported by a grant from the James and Esther King New Investigator grant through the Florida Department of Health and by the Miles for Moffitt Foundation Funds.

"Squamous cell carcinoma of the skin is the second most frequently occurring cancer among Caucasians in the United States, and the numbers of cases continue to rise," said study lead author Dana E. Rollison, Ph.D., Moffitt associate member, vice president and chief health information officer. "Risk factors for SCC include ultraviolet radiation exposure via the sun, older age, light skin and suppressed immune system."

According to the researchers, evidence has been emerging that cutaneous human papillomavirus infection (not the mucosal HPV infection that is associated with cervical cancers) may be an additional risk factor for SCC. Their study investigated antibodies to cutaneous HPV types in five different genera - alpha, beta, gamma, mu and nu - in blood samples from patients with SCC and a control group that did not have SCC.

The study was conducted using 173 SCC cases from a university dermatology clinic and 300 controls who screened negative for skin cancer. Tumor tissue from 159 SCC cases was tested for the presence of cutaneous HPV infection.

The researchers found that SCC was significantly associated with antibodies to HPV 10 in genus alpha and HPV types 8 and 17 in genus beta. Additional associations were found between antibodies to beta HPV types 5 and 24 when SCC cases with those same HPV types in their tumors were compared to controls.

"While our current study provides evidence for an association between genus-beta HPV and SCC, the exact mechanism by which the association exists is still unclear," explained Rollison.

Some researchers hypothesize that infection with the genus-beta HPV has an effect on the repair of DNA in sun-damaged skin, an effect that subsequently leads to an accumulation of mutations that could predispose people to SCC formation.

The study, Rollison said, was unique in that it measured cutaneous HPV types in five different genera and investigated correlations between cutaneous HPV antibodies in the blood and HPV infection in the tumor.

"We hope that this study, aimed at identifying the role of cutaneous HPV infection in SCC, will lead to improved knowledge about who is at risk for SCC and the development of new means of prevention," concluded Rollison and the researchers.


'/>"/>

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
2. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
3. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
4. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
5. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
6. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
7. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
8. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
9. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
10. Moffitt researcher publishes book on nutritional management of cancer treatment effects
11. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, ... In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the ... have extremely low property-tax rates, which contributes to the relatively lower cost of ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/19/2017)... a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed ...   ... Jim Bertolina, ... Tom Tefft ... medical device executive Josh Stopek , PhD, who has led R&D and business development ...
Breaking Medicine Technology: